3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 2
2
Phase 3
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
28
Small Cell Lung Carcinoma
24
Fallopian Tube Neoplasms
12
Uterine Cervical Neoplasms
8
Carcinoma, Ovarian Epithelial
8
Neuroblastoma
7
Lung Neoplasms
6
Sarcoma
3
Neoplasms
3
Retinoblastoma
2
Neoplasm Metastasis
2
Malignant mesenchymal tumor
2
Ganglioneuroblastoma
2
Carcinoma, Non-Small-Cell Lung
2
Solid Tumors
1
SCLC
1
Rhabdomyosarcoma
1
Retinal Neoplasms
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleuropulmonary blastoma
1
Peritoneal Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Localized Extraskeletal Ewing Sarcoma
1
Leukemia
1
Eye Neoplasms
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Endometrial Neoplasms
1
Carcinoma
1
Interventions
Paclitaxel
25
Doxorubicin
15
Carboplatin
14
pembrolizumab
10
Cisplatin
8
Radiotherapy
6
Docetaxel
5
Chemotherapy, Adjuvant
5
Taxes
4
Filgrastim
4
Brachytherapy
4
lenvatinib
3
Observation
3
trastuzumab deruxtecan
2
selinexor
2
olaparib
2
durvalumab
2
Tamoxifen
2
Specimen Handling
2
Ifosfamide
2
Drug Therapy
2
sintilimab
1
sacituzumab govitecan
1
pertuzumab
1
nanocis
1
liposomal doxorubicin
1
ixabepilone
1
gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
dostarlimab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Endometrial Neoplasms
×
Topotecan
×
Clear all
NCT02584478
2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3
Unknown
294 enrolled